DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
TMI is developing the POINT-GUARD, the first and only cerebral embolic protection device with dynamic Double-Edge Sealing. The seal adapts and conforms to complex...
Dr. Kay is a Foot & Ankle surgeon based in Ohio. Like many physicians, he and his colleagues saw better ways to treat patients...
In this episode, host Tobin Arthur is joined by colleague Michael Schmanske in a discussion with DJ Verret, MD, a plastic surgeon and seasoned...
